Skip to main content

The standard treatment for patients with stage II and III newly diagnosed multiple myeloma is chemotherapy induction followed by a single high-dose chemotherapy treatment and autologous stem cell support. Even with this treatment, the complete response rate is approximately 30-35%. Several groups of physicians have evaluated the potential benefit of using 2 cycles of high-dose chemotherapy with autologous stem cell support for patients with multiple myeloma.

Physicians in France performed a clinical trial in which 402 newly diagnosed patients with multiple myeloma were treated with either one cycle of melphalan chemotherapy and total body irradiation or one cycle of high-dose melphalan and one cycle of melphalan and total body irradiation supported by autologous peripheral blood stem cells.

Overall, 85% of patients received the first cycle of high-dose chemotherapy and 78% received both cycles of treatment. The complete remission rate was 39% with 1 cycle of treatment and 49% after 2 cycles of treatment. However, there were no differences in survival between the 2 groups of patients. Good risk patients as evidenced by a low beta 2 microglobulin experienced a 3-year survival of 84% if treated with 2 cycles of treatment compared to 69% for those receiving only 1 cycle of high-dose chemotherapy treatment.

While this study needs additional follow-up for definitive analysis, it suggests that 2 cycles of treatment is of significant benefit to patients who already have a reasonably good outcome, but may not improve the outcomes for patients with more aggressive disease. Different high-dose treatment regimens are currently being evaluated and may be more effective than the ones chosen for this study. (

Scroll to Continue

Recommended Articles

Image placeholder title

Relatlimab Anti-LAG-3 Antibody

Is combination immunotherapy with the anti-LAG-3 antibody relatlimab and Opdivo the next advance in melanoma treatment?

Image placeholder title

Blood Cancers and COVID-19 - What You Need to Know

COCID-19 puts individuals with leukemia, lymphoma, myeloma and MPN's at risk - learn how to optimize your care.

Blood, Vol 94, No 10, Suppl 1, Abstract 3152, pp 714a, 1999)

Copyright © 2018 CancerConnect. All Rights Reserved.